CSTL Castle Biosciences Inc.

Castle Biosciences Inc.

Medical Specialities

Health Care

Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

IPO Year: 2019

Exchange: NASDAQ

Website: castlebiosciences.com

Recent Analyst Ratings for Castle Biosciences Inc.

Date	Price Target	Rating	Analyst
12/14/2023	$25.00	Buy	Guggenheim
1/5/2023	$54.00	Sector Outperform	Scotiabank
1/7/2022	$59.00	Overweight	Stephens & Co.
11/9/2021	$85.00 → $75.00	Outperform	SVB Leerink
7/14/2021	$80.00 → $85.00	Outperform	SVB Leerink

See more ratings

Castle Biosciences Inc.

Recent Analyst Ratings for Castle Biosciences Inc.

Castle Biosciences Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Cole G Bradley converted options into 8,673 shares, increasing direct ownership by 65% to 21,964 units (SEC Form 4)

Director Bradbury Daniel converted options into 8,673 shares (SEC Form 4)

Director Cotton Rodney converted options into 8,673 shares, increasing direct ownership by 163% to 14,002 units (SEC Form 4)

Director Caple Kim converted options into 8,673 shares, increasing direct ownership by 63% to 22,454 units (SEC Form 4)

Director Goldberg Ellen converted options into 8,673 shares, increasing direct ownership by 47% to 27,254 units (SEC Form 4)

Director Olson Tiffany converted options into 8,673 shares, increasing direct ownership by 50% to 25,906 units (SEC Form 4)

Director Harrison Miles converted options into 8,673 shares, increasing direct ownership by 65% to 21,964 units (SEC Form 4)

SEC Form 4 filed by Director Cotton Rodney

Pres. & Chief Exec. Officer Maetzold Derek J sold $121,448 worth of shares (5,644 units at $21.52), decreasing direct ownership by 2% to 74,627 units (SEC Form 4)

Pres. & Chief Exec. Officer Maetzold Derek J sold $113,932 worth of shares (5,644 units at $20.19), decreasing direct ownership by 2% to 75,863 units (SEC Form 4)

Castle Biosciences Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Guggenheim initiated coverage on Castle Biosciences with a new price target

Scotiabank initiated coverage on Castle Biosciences with a new price target

Stephens & Co. initiated coverage on Castle Biosciences with a new price target

SVB Leerink reiterated coverage on Castle Biosciences with a new price target

SVB Leerink reiterated coverage on Castle Biosciences with a new price target

Lake Street initiated coverage on Castle Biosciences with a new price target

Robert W. Baird reiterated coverage on Castle Biosciences with a new price target

KeyBanc reiterated coverage on Castle Biosciences with a new price target

Canaccord Genuity reiterated coverage on Castle Biosciences with a new price target

Castle Biosciences Inc. SEC Filings

Castle Biosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by Castle Biosciences Inc.

SEC Form 10-Q filed by Castle Biosciences Inc.

Castle Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form SCHEDULE 13G filed by Castle Biosciences Inc.

SEC Form DEFA14A filed by Castle Biosciences Inc.

SEC Form DEF 14A filed by Castle Biosciences Inc.

SEC Form 144 filed by Castle Biosciences Inc.

SEC Form PRE 14A filed by Castle Biosciences Inc.

SEC Form 144 filed by Castle Biosciences Inc.